RAPP (Rapport Therapeutics) Short Ratio


RAPP Rapport Therapeutics Inc RAPP
14 GF Score
Price $41.79
! 3 Warning Signs
View Full Analysis

What is Rapport Therapeutics Short Ratio?

Short Ratio is a metric signaling prevailing investors' sentiment with a company. It represents the number of days it takes short sellers on average to repurchase all the shares short.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

RAPP
14GF Score
Rapport Therapeutics Inc RAPP
Short Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Rapport Therapeutics Business Description

Address 99 High Street, Suite 2100, Boston, MA, USA, 02110
Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.
14GF Score

Get the complete analysis for RAPP

Short Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$41.79
Price